68Ga-TCR-FAPI

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug Name68Ga-TCR-FAPI
Drug Alias Name68Ga-TCR-FAPI
ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionPositron-emission tomography enhancersFibroblast activation protein alpha inhibitors
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTumor Research Institute Chinese Academy Of Medical Sciences
China Registration ClassN/A

Develop Information

Active CompaniesCancer Hospital Of Chinese Academy Of Medical Sciences
Inactive CompaniesN/A
Active IndicationsMedullary thyroid cancer (MTC)
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A